Azvudine

Generic Name: Azvudine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₁FN_₆O_₄

CAS Number: 1011529-10-4

Unique Ingredient Identifier: IJ2XP0ID0K

Background: Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

Indication: ⑴用于与核苷逆转录酶抑制剂及非核苷逆转录酶抑制剂联用，治疗高病毒载量的成年HIV-1感染患者。

⑵用于治疗普通型新型冠状病毒肺炎（COVID-19）成年患者。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected

716 patients were classified into nirmatrelvir-ritonavir (NR) and azvudine (FNC) groups. NR patients were older and had more severe disease at baseline. Drug administration was quicker in NR. No significant differences in 28-day mortality or clinical outcomes were found between groups. NR had more side effects, particularly decreased platelet levels.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy